Hepatic encephalopathy
ICD-10 K72.9 · ICD-11 DB99.5

Treatment of Hepatic Encephalopathy in Cirrhosis-Related Parkinsonism

Clinical Scenario

This protocol addresses hepatic encephalopathy in patients who also present with cirrhosis-related Parkinsonism — a distinct motor syndrome that can emerge as a complication of advanced liver disease.

Specific Situation

When Parkinsonism-like motor features arise in the setting of cirrhosis, they define a specific clinical sub-population requiring a targeted therapeutic approach distinct from standard hepatic encephalopathy management.

Clinical guidelines support testing a dedicated neurological intervention in these patients (strong recommendation, 95% consensus).

Treatment Approach & Goal

A dopaminergic approach is the recommended intervention for this scenario. The full regimen — including agent selection, titration sequence, and duration — is detailed in the complete structured protocol.

The defined treatment goal is a >30% reduction in the baseline UPDRS motor score at 12 weeks of therapy.

The complete regimen and titration guidance are available in the protocol below.
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jhep.2022.06.001

  1. In patients with cirrhosis-related Parkinsonism, dopaminergic treatment should be tested (LoE 2, strong recommendation, 95% consensus).
  2. A RCT included 6 patients treated for 8–12 weeks with 15 mg bromocriptine/day after increasing the daily dose from 2.5 mg to 15 mg over a time period of 16 days.
  3. In conclusion, there is evidence for a benefit of bromocriptine treatment in patients with cirrhosis-related Parkinsonism.
  4. Response to treatment was defined as a >30% reduction in the baseline UPDRS motor score at 12 weeks of therapy.
View source ↗